Diabetes Treatments: World Drug Market 2013-2023
How to find trends, opportunities and revenue prospects in treating diabetes
Where's the diabetic treatments market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities.
Our study lets you assess sales data and predictions for the world antidiabetic medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.
Established and emerging diabetes-treating drugs have potential. Read on to scan features of their industry, find what drives it, and see what its future market could be worth.
Forecasts and other analyses to help you understand the diabetes drugs market
Our report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developments (R&D). You also gain 64 tables, 69 charts and two research interviews.
Do you want to find sales potential? With our analysis you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you assess trends, innovations and opportunities for treating diabetes. You see what's happening, discovering possibilities.
There's rising need worldwide for drugs to treat human diabetes. For those agents, our work helps you find business areas that can prosper most, reducing the risk of your missing out.
The following sections show how you benefit from the new study.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market for treating diabetes, that work shows individual forecasts to 2023 for seven submarkets:
See prospects for manufacturers of novel drugs, generics and biosimilars, including follow-on and next-generation products.
Also, our investigation discusses what stimulates and restrains business. In addition, it lets you see what products are likely to achieve the most success.
See revenue forecasts for 25 leading drugs
How will leading antidiabetic agents perform to 2023 at world level? Our study forecasts individual sales of 25 products, including these brands:
Our report also divides its overall world revenue forecast into main geographical markets.
What prospects for leading regions and countries?
In developed and developing countries - especially India and China - there remain many opportunities for developing, manufacturing and selling diabetes treatments. There you see outlooks for producers and sellers of antidiabetic medicines.
Our analyses show you individual revenue forecasts to 2023 for eleven national markets:
Our forecasting shows revenue growth will occur in established pharma markets and in developing countries. In particular, product launches from 2013 to 2023 will change prescribing of antidiabetics and the commercial landscape for those medicines. See how.
Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs treating diabetes? In our study you see developmental trends for antidiabetic agents:
See, then, what the future holds. For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing many issues.
What affects the antidiabetics sector?
Our report discusses issues and events affecting that industry and market from 2013, including these developments:
Also, you analyse the diabetes treatment industry's strengths, weaknesses, opportunities and threats (SWOT). See, then, what the future holds.
Leading companies and 2017 market value
What happens next? Our study predicts the world market for antidiabetic drugs will reach $55.3bn overall in 2017 - with strong growth - and expand further to 2023. See how high revenues can go.
The analyses also show you what products and organisations hold greatest potential. Our work explores companies, including these:
Ten ways Diabetes Treatments: World Drug Market 2013-2023 helps you
To sum up, then, our investigation gives you the following knowledge:
That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.
Ordering now lets you discover predictions to 2023 for diabetes trends and revenues
Our report is for everyone needing analysis of the industry and market for treating diabetes and related metabolic disorders. There you find data, trends, opportunities and predictions. Please order that report now.
Visiongain is a trading partner with the US Federal Government
Where's the diabetic treatments market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities.
Our study lets you assess sales data and predictions for the world antidiabetic medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.
Established and emerging diabetes-treating drugs have potential. Read on to scan features of their industry, find what drives it, and see what its future market could be worth.
Forecasts and other analyses to help you understand the diabetes drugs market
Our report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developments (R&D). You also gain 64 tables, 69 charts and two research interviews.
Do you want to find sales potential? With our analysis you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you assess trends, innovations and opportunities for treating diabetes. You see what's happening, discovering possibilities.
There's rising need worldwide for drugs to treat human diabetes. For those agents, our work helps you find business areas that can prosper most, reducing the risk of your missing out.
The following sections show how you benefit from the new study.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market for treating diabetes, that work shows individual forecasts to 2023 for seven submarkets:
- Human insulins and analogues
- Alpha-glucosidase inhibitors
- Biguanides
- DPP-4 inhibitors
- Meglitinides
- Sulphonylureas
- Thiazolidinediones (glitazones).
See prospects for manufacturers of novel drugs, generics and biosimilars, including follow-on and next-generation products.
Also, our investigation discusses what stimulates and restrains business. In addition, it lets you see what products are likely to achieve the most success.
See revenue forecasts for 25 leading drugs
How will leading antidiabetic agents perform to 2023 at world level? Our study forecasts individual sales of 25 products, including these brands:
- Lantus
- NovoLog
- Humalog
- Levemir
- Glucobay
- Basen
- Januvia
- Prandin
- Actos.
Our report also divides its overall world revenue forecast into main geographical markets.
What prospects for leading regions and countries?
In developed and developing countries - especially India and China - there remain many opportunities for developing, manufacturing and selling diabetes treatments. There you see outlooks for producers and sellers of antidiabetic medicines.
Our analyses show you individual revenue forecasts to 2023 for eleven national markets:
- US
- Japan
- Germany, France, UK, Italy and Spain (EU5)
- Brazil, Russia, India and China (BRIC).
Our forecasting shows revenue growth will occur in established pharma markets and in developing countries. In particular, product launches from 2013 to 2023 will change prescribing of antidiabetics and the commercial landscape for those medicines. See how.
Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs treating diabetes? In our study you see developmental trends for antidiabetic agents:
- Human insulins and analogues
- DPP-4 inhibitors
- Glucagon-like peptide (GLP)-1 agonists
- Sodium glucose co-transporter (SGLT)-2 inhibitors.
See, then, what the future holds. For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing many issues.
What affects the antidiabetics sector?
Our report discusses issues and events affecting that industry and market from 2013, including these developments:
- Rising disease incidence and prevalence, including trends for obesity
- Demand for therapies in developing countries, esp. China
- Insulin analogues and other biotechnological advances
- Biosimilar insulins - changing patterns in competition
- Combination therapies for diabetes
- New drug delivery methods for insulins.
- Improvements to healthcare in developing countries
- R&D progress - potential to improve therapy
- Product safety - e.g. cardiovascular risk - and regulatory affairs
- Disease awareness affecting levels of diagnosis
- Reimbursement for the medicines - issues for payers
- Competition from generic drugs - threats and opportunities
- Secondary uses for antidiabetic medicines.
Also, you analyse the diabetes treatment industry's strengths, weaknesses, opportunities and threats (SWOT). See, then, what the future holds.
Leading companies and 2017 market value
What happens next? Our study predicts the world market for antidiabetic drugs will reach $55.3bn overall in 2017 - with strong growth - and expand further to 2023. See how high revenues can go.
The analyses also show you what products and organisations hold greatest potential. Our work explores companies, including these:
- Novo Nordisk
- Eli Lilly
- Sanofi
- Bayer
- Takeda
- Merck & Co.
- Novartis
- Pfizer.
Ten ways Diabetes Treatments: World Drug Market 2013-2023 helps you
To sum up, then, our investigation gives you the following knowledge:
- Revenues to 2023 for the world market for antidiabetic drugs - discover that industry's overall sales prospects
- Revenues to 2023 for 7 world-level submarkets - investigate the potential of that industry's components, finding the most promising areas for investments and revenues
- Revenues to 2023 for 25 leading products - find sales outlooks for top brands, seeing how they can compete and succeed
- Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see national sales potentials, finding the best regions for revenues and growth
- Review of R&D for treating diabetes - investigate progress in its research areas, finding technological and medical possibilities
- Discussions and data for leading companies - hear about participants' strategies, capabilities, results and outlooks
- Interviews with authorities in that field - discover debates and opinions to help you stay ahead
- Competition and opportunities - see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
- Analysis of what stimulates and restrains the industry and market - assess challenges and strengths, helping you compete and gain advantages
- Prospects for established competitors and firms seeking to enter the sector -explore needs, practices and outlooks for future success.
That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.
Ordering now lets you discover predictions to 2023 for diabetes trends and revenues
Our report is for everyone needing analysis of the industry and market for treating diabetes and related metabolic disorders. There you find data, trends, opportunities and predictions. Please order that report now.
Visiongain is a trading partner with the US Federal Government
1. EXECUTIVE SUMMARY
1.1 Diabetes Drug Treatments: World Market Review
1.2 Content of the Report Chapters
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. INTRODUCTION TO DIABETES AND ANTIDIABETIC DRUGS
2.1 What is Diabetes?
2.1.1 How is Diabetes Classified?
2.2 Disease Symptoms
2.3 Leading Risk Factors for Diabetes
2.3.1 Type 1 Diabetes
2.3.2 Type 2 Diabetes
2.4 Diagnosing Diabetes: Identifying the Presence of Biological Markers
2.5 Incidence and Prevalence Patterns in Diabetes
2.6 The Economic Burden of Diabetes
2.7 Leading Classes of Diabetic Medications
2.7.1 Type 1 Medications
2.7.1.1 Insulin
2.7.1.2 Oral Medications
2.7.1.3 Surgical Options
2.7.2 Type 2 Medications
2.7.2.1 Alpha-glucosidase Inhibitors
2.7.2.2 Biguanides
2.7.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.7.2.4 Meglitinides
2.7.2.5 Sulphonylureas
2.7.2.6 Thiazolidinediones
2.7.2.7 Other (Injectable) Medications
3. THE WORLD DIABETES DRUG MARKET, 2013-2023
3.1 The World Diabetes Drug Market, 2011
3.1.1 The Diabetes Treatment Market by Drug Class, 2011
3.2 Top Selling Diabetes Drugs, 2011
3.3 The Global Diabetes Drug Market: Revenue Forecast, 2012-2023
3.3.1 The Global Diabetes Drug Market: Industry Trends, 2013-2023
3.3.1.1 Insulins to Maintain Market Dominance
3.3.1.2 DPP-4 Inhibitors: Targeting Developing Countries
4. HUMAN INSULINS AND ANALOGUES MARKET, 2013-2023
4.1 Human Insulins and Analogues Market, 2011
4.2 Human Insulins and Analogues: Revenue Forecast, 2012-2023
4.2.1 Human Insulins and Analogues: Market Trends, 2013-2023
4.2.1.1 Novel Methods of Insulin Delivery in Pipeline
4.2.1.2 New Insulin Analogues to Enter the Market in 2013-2014
4.2.1.3 Biosimilar Insulins: A Revolutionary Treatment Option on the Horizon?
4.2.1.4 Targeting China Offers Vast Market Prospects for Players
4.3 Lantus (Insulin Glargine; Sanofi)
4.3.1 Lantus: Revenue Forecast, 2012-2023
4.4 NovoLog (Insulin Aspart; Novo Nordisk)
4.4.1 NovoLog: Revenue Forecast, 2012-2023
4.5 Humalog (Insulin lispro; Eli Lilly)
4.5.1 Humalog: Revenue Forecast, 2012-2023
4.6 Levemir (Insulin detemir; Novo Nordisk)
4.6.1 Levemir: Revenue Forecast, 2012-2023
4.7 Humulin (Insulin isophane; Eli Lilly)
4.7.1 Humulin: Revenue Forecast, 2012-2023
4.8 Apidra (Insulin glulisine; Sanofi)
4.8.1 Apidra: Revenue Forecast, 2012-2023
5. ALPHA-GLUCOSIDASE INHIBITORS MARKET, 2013-2023
5.1 Alpha-glucosidase Inhibitors Market, 2011
5.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2012-2023
5.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2013-2023
5.2.1.1 Concerns over Gastrointestinal Side Effects May Limit Market Acceptance
5.3 Glucobay (Acarbose; Bayer AG)
5.3.1 Glucobay: Revenue Forecast, 2012-2023
5.4 Basen (Voglibose; Takeda)
5.4.1 Basen: Revenue Forecast, 2012-2023
5.5 Miglitol (Glyset)
5.5.1 Miglitol: Revenue Forecast, 2012-2023
5.6 Precose (Acarbose; Bayer)
5.6.1 Precose: Revenue Forecast, 2012-2023
6. BIGUANIDES MARKET, 2013-2023
6.1 Biguanides Market, 2011
6.2 Biguanides: Revenue Forecast, 2012-2023
6.2.1 Biguanides: Market Trends, 2013-2023
6.2.1.1 Strong Efficacy in Treating Severe Hypoglycaemic Attacks
6.3 Glucophage (Metformin; Merck & Co.)
6.3.1 Glucophage: Revenue Forecast, 2012-2023
6.4 Fortamet (Metformin hydrochloride; Shionogi & Company)
6.4.1 Fortamet: Revenue Forecast, 2012-2023
6.5 Glumetza (Metformin hydrochloride; Santarus Inc.)
6.5.1 Glumetza: Revenue Forecast, 2012-2023
6.6 Diabex (Metformin hydrochloride; Alphapharm)
6.6.1 Diabex: Revenue Forecast, 2012-2023
7. DPP-4 INHIBITORS MARKET, 2013-2023
7.1 DPP-4 Inhibitors Market, 2011
7.2 DPP-4 Inhibitors: Revenue Forecast, 2012-2023
7.2.1 DPP-4 Inhibitors: Market Trends, 2013-2023
7.2.1.1 Displacing Metformins' Leading Position
7.2.1.2 Disparity Between Drugs May Restrict the Market
7.3 Januvia (Sitagliptin; Merck & Co.)
7.3.1 Januvia: Revenue Forecast, 2012-2023
7.4 Galvus (Vildagliptin; Novartis)
7.4.1 Galvus: Revenue Forecast, 2012-2023
7.5 Glactiv (Sitagliptin; Ono Pharmaceuticals & Banyu Pharmaceuticals)
7.5.1 Glactiv: Revenue Forecast, 2012-2023
8. MEGLITINIDES MARKET, 2013-2023
8.1 Meglitinides Market, 2011
8.2 Meglitinides: Revenue Forecast, 2012-2023
8.2.1 Meglitinides: Market Trends, 2013-2023
8.2.1.1 Combination Therapy: The Future Direction for Meglitinides?
8.3 Prandin (Repaglinide; Novo Nordisk)
8.3.1 Prandin: Revenue Forecast, 2012-2023
8.4 Starlix (Nateglinide; Novartis)
8.4.1 Starlix: Revenue Forecast, 2012-2023
8.5 Glufast (Mitiglinide; Kissei Pharmaceuticals and Takeda)
8.5.1 Glufast: Revenue Forecast, 2012-2023
9. SULPHONYLUREAS MARKET, 2013-2023
9.1 Sulphonylureas Market, 2011
9.2 Sulphonylureas: Revenue Forecast, 2012-2023
9.2.1 Sulphonylureas: Market Trends, 2013-2023
9.2.1.1 Cardiovascular Complications May Affect Sales
9.3 Diamicron (Gliclazide; Servier)
9.3.1 Diamicron: Revenue Forecast, 2012-2023
9.4 Amaryl (Glimepiride; Sanofi)
9.4.1 Amaryl: Revenue Forecast, 2012-2023
9.5 Glucotrol XL (Glipizide; Pfizer)
9.5.1 Glucotrol XL: Revenue Forecast, 2012-2023
10. THIAZOLIDINEDIONES MARKET, 2013-2023
10.1 Thiazolidinediones Market, 2011
10.2 Thiazolidinediones: Revenue Forecast, 2012-2023
10.2.1 Thiazolidinediones: Market Trends, 2013-2023
10.2.1.1 Possible Drug Efficacy in Prediabetes?
10.2.1.2 Full Clinical Value Needs to be Addressed
10.3 Actos (Pioglitazone; Takeda)
10.3.1 Actos: Revenue Forecast, 2012-2023
10.4 Avandia (Rosiglitazone; GSK)
10.4.1 Avandia: Revenue Forecast, 2012-2023
11. LEADING NATIONAL DIABETES DRUG MARKETS, 2013-2023
11.1 Leading National Markets for Antidiabetic Drugs, 2011
11.2 Leading National Markets: Revenue Forecasts, 2012-2023
11.3 The US is the Largest Market for Antidiabetic Drugs
11.4 The Japanese Market
11.4.1 Increased Governmental Investments Will Drive Market
11.4.2 Novel Treatment Options Entering the Drug Landscape
11.5 Leading EU Markets for Antidiabetic Drugs: Revenues, 2011
11.5.1 The EU5 Market: Revenue Forecasts, 2012-2023
11.5.1.1 Germany: Disease Prevention Measures Require Improvement
11.5.1.2 UK: Trend of Combination Therapy
11.5.1.3 The Market in France and Regulatory Reform
11.5.1.4 Patient Incentives in Italy to Drive Diabetes Market
11.5.1.5 Cost-containment Measures in Spain Discouraging Companies?
11.6 China: The World's Largest Diabetic Population
11.6.1 Increased Presence of Multinational Corporations
11.6.2 Multi-Billion Dollar Investment to Improve Healthcare
11.7 India: Merck & Co. Leading the Way
11.7.1 Focusing on India's Rural Population
11.8 Strong Antidiabetic Drug Pipeline in Russia
11.8.1 Heavy Burden on Russian Patients May Reduce Compliance
11.9 Brazil: Regional Differences in Healthcare Access
11.9.1 Initiatives to Improve Awareness Gather Pace
12. THE DIABETES DRUG MARKET: R&D PIPELINE, 2013
12.1 Discovering New Treatments and Molecular Targets
12.2 Human Insulins and Analogues: Pipeline Developments
12.2.1 LY2605541 (Eli Lilly/Boehringer Ingelheim)
12.2.2 Tresiba (Novo Nordisk)
12.2.3 LY2963016 (Eli Lilly/Boehringer Ingelheim)
12.3 DPP-4 Inhibitors: Pipeline Developments
12.3.1 Nesina (Takeda/Furiex Pharmaceuticals)
12.3.2 Trelagliptin (Takeda/Furiex Pharmaceuticals)
12.3.3 MK-3102 (Merck & Co.)
12.4 Other Novel Drug Targets
12.4.1 Glucagon-like Peptide (GLP)-1 Agonists
12.4.1.1 Albiglutide (formerly Syncria; GSK)
12.4.1.2 Dulaglutide (LY2189265; Eli Lilly)
12.4.1.3 Lixisenatide (Lyxumia; Sanofi)
12.4.1.4 Semaglutide (NN9535; Novo Nordisk)
12.4.2 Sodium Glucose Co-Transporter (SGLT)-2 Inhibitors
12.4.2.1 Ipragliflozin (ASP1941; Astellas Pharma/Kotobuki)
12.4.2.2 Canagliflozin (Invokana; Johnson & Johnson)
12.4.2.3 Empagliflozin (BI10773; Eli Lilly/Boehringer Ingelheim)
12.4.2.4 Dapagliflozin (Forxiga; Bristol-Myers Squibb/AstraZeneca)
13. DIABETES DRUG MARKET: INDUSTRY TRENDS, 2013-2023
13.1 SWOT Analysis of the Diabetes Drug Market, 2013-2023
13.2 Strengths
13.2.1 Promising R&D Pipelines
13.2.2 Secondary Indications
13.2.3 Market Competition
13.3 Weaknesses
13.3.1 Lack of Disease Awareness
13.3.2 Reimbursement Issues
13.3.3 Increased Risk of Cardiovascular Events
13.4 Opportunities
13.4.1 Rising Disease Prevalence
13.4.2 Increased Demand in Pharmerging Markets
13.4.3 Novel Insulin Delivery Methods
13.5 Threats
13.5.1 Type 1 Diabetes Vaccine
13.5.2 Competition from Generic Drugs
13.5.3 Greater Regulatory Scrutiny
13.6 STEP Analysis of the World Diabetes Drug Market, 2013-2023
13.6.1 Social Development
13.6.2 Technological Advances
13.6.3 Economic Pressures
13.6.4 Political Issues
14. RESEARCH INTERVIEWS
14.1 Interview with an Academic Involved in Diabetes R&D
14.1.1 The Insulin Drug Market
14.1.2 Novel Delivery Technologies
14.1.3 Future Developments and Market Prospects
14.2 Interview with James Anderson, Generex Biotech
14.2.1 The Current Diabetes Drug Market
14.2.2 Generex's Oral-lyn™ Product and Buccal Drug Delivery
15. CONCLUSIONS
15.1 The Diabetes Drugs Market - Recent Results
15.2 Outlook for the World Diabetes Drugs Market, 2013-2023
15.2.1 Insulins Will Continue to Dominate the Market
15.3 Regional Outlook for The Diabetes Drugs Market, 2013-2023
15.4 Future Opportunities for Diabetes Drug Manufacturers
1.1 Diabetes Drug Treatments: World Market Review
1.2 Content of the Report Chapters
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. INTRODUCTION TO DIABETES AND ANTIDIABETIC DRUGS
2.1 What is Diabetes?
2.1.1 How is Diabetes Classified?
2.2 Disease Symptoms
2.3 Leading Risk Factors for Diabetes
2.3.1 Type 1 Diabetes
2.3.2 Type 2 Diabetes
2.4 Diagnosing Diabetes: Identifying the Presence of Biological Markers
2.5 Incidence and Prevalence Patterns in Diabetes
2.6 The Economic Burden of Diabetes
2.7 Leading Classes of Diabetic Medications
2.7.1 Type 1 Medications
2.7.1.1 Insulin
2.7.1.2 Oral Medications
2.7.1.3 Surgical Options
2.7.2 Type 2 Medications
2.7.2.1 Alpha-glucosidase Inhibitors
2.7.2.2 Biguanides
2.7.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.7.2.4 Meglitinides
2.7.2.5 Sulphonylureas
2.7.2.6 Thiazolidinediones
2.7.2.7 Other (Injectable) Medications
3. THE WORLD DIABETES DRUG MARKET, 2013-2023
3.1 The World Diabetes Drug Market, 2011
3.1.1 The Diabetes Treatment Market by Drug Class, 2011
3.2 Top Selling Diabetes Drugs, 2011
3.3 The Global Diabetes Drug Market: Revenue Forecast, 2012-2023
3.3.1 The Global Diabetes Drug Market: Industry Trends, 2013-2023
3.3.1.1 Insulins to Maintain Market Dominance
3.3.1.2 DPP-4 Inhibitors: Targeting Developing Countries
4. HUMAN INSULINS AND ANALOGUES MARKET, 2013-2023
4.1 Human Insulins and Analogues Market, 2011
4.2 Human Insulins and Analogues: Revenue Forecast, 2012-2023
4.2.1 Human Insulins and Analogues: Market Trends, 2013-2023
4.2.1.1 Novel Methods of Insulin Delivery in Pipeline
4.2.1.2 New Insulin Analogues to Enter the Market in 2013-2014
4.2.1.3 Biosimilar Insulins: A Revolutionary Treatment Option on the Horizon?
4.2.1.4 Targeting China Offers Vast Market Prospects for Players
4.3 Lantus (Insulin Glargine; Sanofi)
4.3.1 Lantus: Revenue Forecast, 2012-2023
4.4 NovoLog (Insulin Aspart; Novo Nordisk)
4.4.1 NovoLog: Revenue Forecast, 2012-2023
4.5 Humalog (Insulin lispro; Eli Lilly)
4.5.1 Humalog: Revenue Forecast, 2012-2023
4.6 Levemir (Insulin detemir; Novo Nordisk)
4.6.1 Levemir: Revenue Forecast, 2012-2023
4.7 Humulin (Insulin isophane; Eli Lilly)
4.7.1 Humulin: Revenue Forecast, 2012-2023
4.8 Apidra (Insulin glulisine; Sanofi)
4.8.1 Apidra: Revenue Forecast, 2012-2023
5. ALPHA-GLUCOSIDASE INHIBITORS MARKET, 2013-2023
5.1 Alpha-glucosidase Inhibitors Market, 2011
5.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2012-2023
5.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2013-2023
5.2.1.1 Concerns over Gastrointestinal Side Effects May Limit Market Acceptance
5.3 Glucobay (Acarbose; Bayer AG)
5.3.1 Glucobay: Revenue Forecast, 2012-2023
5.4 Basen (Voglibose; Takeda)
5.4.1 Basen: Revenue Forecast, 2012-2023
5.5 Miglitol (Glyset)
5.5.1 Miglitol: Revenue Forecast, 2012-2023
5.6 Precose (Acarbose; Bayer)
5.6.1 Precose: Revenue Forecast, 2012-2023
6. BIGUANIDES MARKET, 2013-2023
6.1 Biguanides Market, 2011
6.2 Biguanides: Revenue Forecast, 2012-2023
6.2.1 Biguanides: Market Trends, 2013-2023
6.2.1.1 Strong Efficacy in Treating Severe Hypoglycaemic Attacks
6.3 Glucophage (Metformin; Merck & Co.)
6.3.1 Glucophage: Revenue Forecast, 2012-2023
6.4 Fortamet (Metformin hydrochloride; Shionogi & Company)
6.4.1 Fortamet: Revenue Forecast, 2012-2023
6.5 Glumetza (Metformin hydrochloride; Santarus Inc.)
6.5.1 Glumetza: Revenue Forecast, 2012-2023
6.6 Diabex (Metformin hydrochloride; Alphapharm)
6.6.1 Diabex: Revenue Forecast, 2012-2023
7. DPP-4 INHIBITORS MARKET, 2013-2023
7.1 DPP-4 Inhibitors Market, 2011
7.2 DPP-4 Inhibitors: Revenue Forecast, 2012-2023
7.2.1 DPP-4 Inhibitors: Market Trends, 2013-2023
7.2.1.1 Displacing Metformins' Leading Position
7.2.1.2 Disparity Between Drugs May Restrict the Market
7.3 Januvia (Sitagliptin; Merck & Co.)
7.3.1 Januvia: Revenue Forecast, 2012-2023
7.4 Galvus (Vildagliptin; Novartis)
7.4.1 Galvus: Revenue Forecast, 2012-2023
7.5 Glactiv (Sitagliptin; Ono Pharmaceuticals & Banyu Pharmaceuticals)
7.5.1 Glactiv: Revenue Forecast, 2012-2023
8. MEGLITINIDES MARKET, 2013-2023
8.1 Meglitinides Market, 2011
8.2 Meglitinides: Revenue Forecast, 2012-2023
8.2.1 Meglitinides: Market Trends, 2013-2023
8.2.1.1 Combination Therapy: The Future Direction for Meglitinides?
8.3 Prandin (Repaglinide; Novo Nordisk)
8.3.1 Prandin: Revenue Forecast, 2012-2023
8.4 Starlix (Nateglinide; Novartis)
8.4.1 Starlix: Revenue Forecast, 2012-2023
8.5 Glufast (Mitiglinide; Kissei Pharmaceuticals and Takeda)
8.5.1 Glufast: Revenue Forecast, 2012-2023
9. SULPHONYLUREAS MARKET, 2013-2023
9.1 Sulphonylureas Market, 2011
9.2 Sulphonylureas: Revenue Forecast, 2012-2023
9.2.1 Sulphonylureas: Market Trends, 2013-2023
9.2.1.1 Cardiovascular Complications May Affect Sales
9.3 Diamicron (Gliclazide; Servier)
9.3.1 Diamicron: Revenue Forecast, 2012-2023
9.4 Amaryl (Glimepiride; Sanofi)
9.4.1 Amaryl: Revenue Forecast, 2012-2023
9.5 Glucotrol XL (Glipizide; Pfizer)
9.5.1 Glucotrol XL: Revenue Forecast, 2012-2023
10. THIAZOLIDINEDIONES MARKET, 2013-2023
10.1 Thiazolidinediones Market, 2011
10.2 Thiazolidinediones: Revenue Forecast, 2012-2023
10.2.1 Thiazolidinediones: Market Trends, 2013-2023
10.2.1.1 Possible Drug Efficacy in Prediabetes?
10.2.1.2 Full Clinical Value Needs to be Addressed
10.3 Actos (Pioglitazone; Takeda)
10.3.1 Actos: Revenue Forecast, 2012-2023
10.4 Avandia (Rosiglitazone; GSK)
10.4.1 Avandia: Revenue Forecast, 2012-2023
11. LEADING NATIONAL DIABETES DRUG MARKETS, 2013-2023
11.1 Leading National Markets for Antidiabetic Drugs, 2011
11.2 Leading National Markets: Revenue Forecasts, 2012-2023
11.3 The US is the Largest Market for Antidiabetic Drugs
11.4 The Japanese Market
11.4.1 Increased Governmental Investments Will Drive Market
11.4.2 Novel Treatment Options Entering the Drug Landscape
11.5 Leading EU Markets for Antidiabetic Drugs: Revenues, 2011
11.5.1 The EU5 Market: Revenue Forecasts, 2012-2023
11.5.1.1 Germany: Disease Prevention Measures Require Improvement
11.5.1.2 UK: Trend of Combination Therapy
11.5.1.3 The Market in France and Regulatory Reform
11.5.1.4 Patient Incentives in Italy to Drive Diabetes Market
11.5.1.5 Cost-containment Measures in Spain Discouraging Companies?
11.6 China: The World's Largest Diabetic Population
11.6.1 Increased Presence of Multinational Corporations
11.6.2 Multi-Billion Dollar Investment to Improve Healthcare
11.7 India: Merck & Co. Leading the Way
11.7.1 Focusing on India's Rural Population
11.8 Strong Antidiabetic Drug Pipeline in Russia
11.8.1 Heavy Burden on Russian Patients May Reduce Compliance
11.9 Brazil: Regional Differences in Healthcare Access
11.9.1 Initiatives to Improve Awareness Gather Pace
12. THE DIABETES DRUG MARKET: R&D PIPELINE, 2013
12.1 Discovering New Treatments and Molecular Targets
12.2 Human Insulins and Analogues: Pipeline Developments
12.2.1 LY2605541 (Eli Lilly/Boehringer Ingelheim)
12.2.2 Tresiba (Novo Nordisk)
12.2.3 LY2963016 (Eli Lilly/Boehringer Ingelheim)
12.3 DPP-4 Inhibitors: Pipeline Developments
12.3.1 Nesina (Takeda/Furiex Pharmaceuticals)
12.3.2 Trelagliptin (Takeda/Furiex Pharmaceuticals)
12.3.3 MK-3102 (Merck & Co.)
12.4 Other Novel Drug Targets
12.4.1 Glucagon-like Peptide (GLP)-1 Agonists
12.4.1.1 Albiglutide (formerly Syncria; GSK)
12.4.1.2 Dulaglutide (LY2189265; Eli Lilly)
12.4.1.3 Lixisenatide (Lyxumia; Sanofi)
12.4.1.4 Semaglutide (NN9535; Novo Nordisk)
12.4.2 Sodium Glucose Co-Transporter (SGLT)-2 Inhibitors
12.4.2.1 Ipragliflozin (ASP1941; Astellas Pharma/Kotobuki)
12.4.2.2 Canagliflozin (Invokana; Johnson & Johnson)
12.4.2.3 Empagliflozin (BI10773; Eli Lilly/Boehringer Ingelheim)
12.4.2.4 Dapagliflozin (Forxiga; Bristol-Myers Squibb/AstraZeneca)
13. DIABETES DRUG MARKET: INDUSTRY TRENDS, 2013-2023
13.1 SWOT Analysis of the Diabetes Drug Market, 2013-2023
13.2 Strengths
13.2.1 Promising R&D Pipelines
13.2.2 Secondary Indications
13.2.3 Market Competition
13.3 Weaknesses
13.3.1 Lack of Disease Awareness
13.3.2 Reimbursement Issues
13.3.3 Increased Risk of Cardiovascular Events
13.4 Opportunities
13.4.1 Rising Disease Prevalence
13.4.2 Increased Demand in Pharmerging Markets
13.4.3 Novel Insulin Delivery Methods
13.5 Threats
13.5.1 Type 1 Diabetes Vaccine
13.5.2 Competition from Generic Drugs
13.5.3 Greater Regulatory Scrutiny
13.6 STEP Analysis of the World Diabetes Drug Market, 2013-2023
13.6.1 Social Development
13.6.2 Technological Advances
13.6.3 Economic Pressures
13.6.4 Political Issues
14. RESEARCH INTERVIEWS
14.1 Interview with an Academic Involved in Diabetes R&D
14.1.1 The Insulin Drug Market
14.1.2 Novel Delivery Technologies
14.1.3 Future Developments and Market Prospects
14.2 Interview with James Anderson, Generex Biotech
14.2.1 The Current Diabetes Drug Market
14.2.2 Generex's Oral-lyn™ Product and Buccal Drug Delivery
15. CONCLUSIONS
15.1 The Diabetes Drugs Market - Recent Results
15.2 Outlook for the World Diabetes Drugs Market, 2013-2023
15.2.1 Insulins Will Continue to Dominate the Market
15.3 Regional Outlook for The Diabetes Drugs Market, 2013-2023
15.4 Future Opportunities for Diabetes Drug Manufacturers
LIST OF TABLES
Table 2.1 Types of Injectable Insulin, 2013
Table 2.2 Commonly Prescribed Type 2 Diabetic Medications, 2013
Table 2.3 Other Classes of Drugs Used in Type 2 Diabetes, 2013
Table 3.1 The Global Diabetes Treatment Market: Revenues ($m) and Market Shares (%) by Type of Medication, 2011
Table 3.2 The Global Diabetes Treatment Market: Revenues ($m) and Market Shares (%) by Drug Class, 2011
Table 3.3 Top-Selling Diabetes Drugs: Revenues ($m) and Market Shares (%), 2011
Table 3.4 Diabetes Treatments: Revenue Forecasts ($bn) by Drug Class, 2012-2023
Table 4.1 Human Insulins and Analogues: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 4.2 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 4.3 Lantus: Drug Revenue Forecast ($bn), 2012-2023
Table 4.4 NovoLog: Drug Revenue Forecast ($bn), 2012-2023
Table 4.5 Humalog: Drug Revenue Forecast ($bn), 2012-2023
Table 4.6 Levemir: Drug Revenue Forecast ($bn), 2012-2023
Table 4.7 Humulin: Drug Revenue Forecast ($bn), 2012-2023
Table 4.8 Apidra: Drug Revenue Forecast ($bn), 2012-2023
Table 5.1 Alpha-glucosidase Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 5.2 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 5.3 Glucobay: Drug Revenue Forecast ($bn), 2012-2023
Table 5.4 Basen: Drug Revenue Forecast ($bn), 2012-2023
Table 5.5 Miglitol: Drug Revenue Forecast ($bn), 2012-2023
Table 5.6 Precose: Drug Revenue Forecast ($bn), 2012-2023
Table 6.1 Biguanides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 6.2 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 6.3 Glucophage: Drug Revenue Forecast ($bn), 2012-2023
Table 6.4 Fortamet: Drug Revenue Forecast ($bn), 2012-2023
Table 6.5 Glumetza: Drug Revenue Forecast ($bn), 2012-2023
Table 6.6 Diabex: Drug Revenue Forecast ($bn), 2012-2023
Table 7.1 DPP-4 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 7.2 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 7.3 Januvia: Drug Revenue Forecast ($bn), 2012-2023
Table 7.4 Galvus: Drug Revenue Forecast ($bn), 2012-2023
Table 7.5 Glactiv: Revenue Forecast ($bn), 2012-2023
Table 8.1 Meglitinides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 8.2 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 8.3 Prandin: Drug Revenue Forecast ($bn), 2012-2023
Table 8.4 Starlix: Drug Revenue Forecast ($bn), 2012-2023
Table 8.5 Glufast: Drug Revenue Forecast ($bn), 2012-2023
Table 9.1 Sulphonylureas: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 9.2 Sulphonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 9.3 Diamicron: Drug Revenue Forecast ($bn), 2012-2023
Table 9.4 Amaryl: Drug Revenue Forecast ($bn), 2012-2023
Table 9.5 Glucotrol XL: Drug Revenue Forecast ($bn), 2012-2023
Table 10.1 Thiazolidinediones: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 10.2 Thiazolidinediones: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 10.3 Actos: Drug Revenue Forecast ($bn), 2012-2023
Table 10.4 Avandia: Drug Revenue Forecast ($bn), 2012-2023
Table 11.1 The Global Diabetes Drugs Market: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 11.2 The Diabetes Drugs Market: Revenue Forecasts ($bn) by Region, 2012-2023
Table 11.3 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.4 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.5 The EU5 Diabetes Drugs Market ($bn), EU5 Market Shares (%) and Global Market Shares (%) by Country, 2011
Table 11.6 The EU5 Diabetes Drugs Market: Revenue Forecasts ($bn) by Leading Country (EU5), 2012-2023
Table 11.7 The German Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.8 The UK Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.9 The French Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.10 The Italian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.11 The Spanish Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.12 The Chinese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.13 The Indian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.14 The Russian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.15 The Brazilian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 13.1 SWOT Analysis of the World Diabetes Drugs Market, 2012-2023
Table 15.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), in 2014, 2017, 2020 and 2023
Table 15.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) and Market Shares (%) in Leading Regional Markets, 2014, 2017, 2020 and 2023
Table 2.1 Types of Injectable Insulin, 2013
Table 2.2 Commonly Prescribed Type 2 Diabetic Medications, 2013
Table 2.3 Other Classes of Drugs Used in Type 2 Diabetes, 2013
Table 3.1 The Global Diabetes Treatment Market: Revenues ($m) and Market Shares (%) by Type of Medication, 2011
Table 3.2 The Global Diabetes Treatment Market: Revenues ($m) and Market Shares (%) by Drug Class, 2011
Table 3.3 Top-Selling Diabetes Drugs: Revenues ($m) and Market Shares (%), 2011
Table 3.4 Diabetes Treatments: Revenue Forecasts ($bn) by Drug Class, 2012-2023
Table 4.1 Human Insulins and Analogues: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 4.2 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 4.3 Lantus: Drug Revenue Forecast ($bn), 2012-2023
Table 4.4 NovoLog: Drug Revenue Forecast ($bn), 2012-2023
Table 4.5 Humalog: Drug Revenue Forecast ($bn), 2012-2023
Table 4.6 Levemir: Drug Revenue Forecast ($bn), 2012-2023
Table 4.7 Humulin: Drug Revenue Forecast ($bn), 2012-2023
Table 4.8 Apidra: Drug Revenue Forecast ($bn), 2012-2023
Table 5.1 Alpha-glucosidase Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 5.2 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 5.3 Glucobay: Drug Revenue Forecast ($bn), 2012-2023
Table 5.4 Basen: Drug Revenue Forecast ($bn), 2012-2023
Table 5.5 Miglitol: Drug Revenue Forecast ($bn), 2012-2023
Table 5.6 Precose: Drug Revenue Forecast ($bn), 2012-2023
Table 6.1 Biguanides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 6.2 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 6.3 Glucophage: Drug Revenue Forecast ($bn), 2012-2023
Table 6.4 Fortamet: Drug Revenue Forecast ($bn), 2012-2023
Table 6.5 Glumetza: Drug Revenue Forecast ($bn), 2012-2023
Table 6.6 Diabex: Drug Revenue Forecast ($bn), 2012-2023
Table 7.1 DPP-4 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 7.2 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 7.3 Januvia: Drug Revenue Forecast ($bn), 2012-2023
Table 7.4 Galvus: Drug Revenue Forecast ($bn), 2012-2023
Table 7.5 Glactiv: Revenue Forecast ($bn), 2012-2023
Table 8.1 Meglitinides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 8.2 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 8.3 Prandin: Drug Revenue Forecast ($bn), 2012-2023
Table 8.4 Starlix: Drug Revenue Forecast ($bn), 2012-2023
Table 8.5 Glufast: Drug Revenue Forecast ($bn), 2012-2023
Table 9.1 Sulphonylureas: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 9.2 Sulphonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 9.3 Diamicron: Drug Revenue Forecast ($bn), 2012-2023
Table 9.4 Amaryl: Drug Revenue Forecast ($bn), 2012-2023
Table 9.5 Glucotrol XL: Drug Revenue Forecast ($bn), 2012-2023
Table 10.1 Thiazolidinediones: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011
Table 10.2 Thiazolidinediones: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023
Table 10.3 Actos: Drug Revenue Forecast ($bn), 2012-2023
Table 10.4 Avandia: Drug Revenue Forecast ($bn), 2012-2023
Table 11.1 The Global Diabetes Drugs Market: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 11.2 The Diabetes Drugs Market: Revenue Forecasts ($bn) by Region, 2012-2023
Table 11.3 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.4 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.5 The EU5 Diabetes Drugs Market ($bn), EU5 Market Shares (%) and Global Market Shares (%) by Country, 2011
Table 11.6 The EU5 Diabetes Drugs Market: Revenue Forecasts ($bn) by Leading Country (EU5), 2012-2023
Table 11.7 The German Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.8 The UK Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.9 The French Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.10 The Italian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.11 The Spanish Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.12 The Chinese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.13 The Indian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.14 The Russian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 11.15 The Brazilian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023
Table 13.1 SWOT Analysis of the World Diabetes Drugs Market, 2012-2023
Table 15.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), in 2014, 2017, 2020 and 2023
Table 15.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) and Market Shares (%) in Leading Regional Markets, 2014, 2017, 2020 and 2023
Brazil: Regional Differences in Healthcare Access
The Brazil market for diabetes drugs was valued $0.65bn in 2011. Between 2011 and 2023, the market will grow with a CAGR of 5.1%, reaching $1.18bn by the end of the forecast period.
As with Russia, in Brazil, once diagnosed with diabetes, all supplies and treatment-related costs are provided by the patient. As most of the supplies and treatments are imported, and are at premium prices, this poses a significant problem for those patients who are from rural parts of the country that can not afford the costs associated with the management of their condition. Since 2006, and the introduction of the federal Law No. 11,347, medications and supplies needed for the control and monitoring of diabetes can now be distributed free. However, besides being a large country, the regions of Brazil are different in terms of culture, geography and economics, and more economically developed regions, such as São Paulo and the other Southeast states have easier access to such medicines and education in comparison with other regions of the country. In response to this, in 2011 the president of Brazil reportedly announced plans to provide free medications for everyone suffering from diabetes and high blood pressure, by distributing the medications through a nationwide network of budget pharmacies where many drugs are already sold at a 90% discount. The free medicines will be available to all Brazilians who have a doctor's prescription.
Initiatives to Improve Awareness Gather Pace
One of the key factors that will restrict growth of the diabetes drug market in Brazil is the apparentlong delays in the drug approval process and that patent applications can take up to seven years prior to market approval. However an aging population and growing middle class represent an attractive target market. Furthermore, as the Brazilian economy grows, the country’s pharmaceutical market will continue to experience robust growth, which will attract many foreign players into the region, which is largely open and unrestricted to multinational companies. However, due to the lack of government support in the country, these companies have mostly partnered with local players for the expansion of their services. Another concern for the diabetes drug market in Brazil is the lack of awareness. Indeed, a worrying trend in the country has been that the prevalence of diabetes has outpaced disease awareness. Novartis, the manufacturer of Galvus, sought to raise awareness by creating several communications initiatives to engage multiple stakeholders, including providing comprehensive clinical data to key opinion leaders (KOLs) and physicians, offering product samples to physicians and inviting medical professionals to attend the American Diabetes Association congress in the US, to learn more about the disease and treatment options.
